JMP Securities Reiterates Buy Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “buy” rating reaffirmed by analysts at JMP Securities in a research report issued on Monday, TipRanks reports. They presently have a $23.00 target price on the biopharmaceutical company’s stock. JMP Securities’ price objective points to a potential upside of 95.74% from the stock’s current price.

Several other research firms have also commented on MRNS. Truist raised their price objective on shares of Marinus Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, August 18th. Robert W. Baird reaffirmed a “buy” rating and issued a $32.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, August 19th. Truist Securities raised their target price on shares of Marinus Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 18th. Zacks Investment Research cut shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 14th. Finally, SVB Leerink reaffirmed a “buy” rating on shares of Marinus Pharmaceuticals in a report on Thursday, August 19th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $29.11.

NASDAQ MRNS opened at $11.75 on Monday. The firm has a 50 day simple moving average of $13.31 and a 200-day simple moving average of $15.24. The company has a debt-to-equity ratio of 0.12, a quick ratio of 7.24 and a current ratio of 7.24. Marinus Pharmaceuticals has a one year low of $10.61 and a one year high of $20.04. The firm has a market cap of $431.60 million, a price-to-earnings ratio of -4.80 and a beta of 1.21.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.03. Equities analysts predict that Marinus Pharmaceuticals will post -2.79 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Morgan Stanley grew its position in Marinus Pharmaceuticals by 22.7% in the 2nd quarter. Morgan Stanley now owns 84,161 shares of the biopharmaceutical company’s stock valued at $1,509,000 after buying an additional 15,593 shares during the last quarter. Jefferies Group LLC purchased a new position in Marinus Pharmaceuticals in the 2nd quarter valued at $274,000. Invesco Ltd. purchased a new position in Marinus Pharmaceuticals in the 2nd quarter valued at $210,000. Lion Point Capital LP grew its position in Marinus Pharmaceuticals by 0.4% in the 2nd quarter. Lion Point Capital LP now owns 3,631,694 shares of the biopharmaceutical company’s stock valued at $65,152,000 after buying an additional 13,360 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY boosted its position in shares of Marinus Pharmaceuticals by 154,700.0% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 10,836 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 10,829 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.

Featured Article: How does inflation affect different investments?

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.